摘要
目的探讨布地奈德福英特罗联合百令胶囊治疗稳定期老年慢性阻塞性肺疾病患者的临床疗效和安全性.方法将124例稳定期老年慢性阻塞性肺疾病患者按随机数字表法分为观察组与对照组,每组62例,均给于常规治疗及对症治疗,对照组在此基础上给予布地奈德福莫特罗吸入剂治疗,观察组在对照组基础上给予百令胶囊治疗,观察12周.治疗后比较两组临床疗效,检测治疗前后两组第1 s用力呼吸容积、第1 s用力呼吸容积占预计值百分比、第1 s用力呼吸容积占用力呼气肺活量百分比的变化,治疗期间随时记录不良反应发生状况.结果治疗后观察组总有效率(95.2%)显著高于对照组(82.3%)(P<0.05);治疗后两组第1 s用力呼吸容积、第1 s用力呼吸容积占预计值百分比、第1 s用力呼吸容积占用力呼气肺活量百分比均较治疗前显著升高(P<0.01),观察组显著高于对照组(P<0.01);治疗期间两组心悸、头痛、震颤、咽部刺激等不良反应发生率比较差异无统计学意义(P>0.05).结论布地奈德福莫特罗联合百令胶囊治疗稳定期老年慢性阻塞性肺疾病患者疗效确切,安全性高,值得在临床推广应用.
Objective To investigate the effect of budesonide formoterol combined with Bailing capsule in the treatment of elderly patients with stable COPD. Methods A total of 124 elderly patients with stable COPD were divided into observation group and control group according to the random number table meth-od, with 62 cases in each group. On the basis of conventional treatment and symptomatic treatment in the two groups, the control group was treated with budesonide formoterol inhalation therapy, and the obser-vation group was plus Bailing capsule. Patients were observed for 12 weeks. The clinical efficacy and lung function before and after treatment [1st s force respiratory volume (FEV1), FEV1 as a percentage of pre-dicted value (FEV1%), FEV1 occupational expiratory vital capacity percentage (FEV1/FVC)], incidence of adverse reactions during treatment of the two groups were compared. Results The total effective rate of the observation group was 95. 2%, higher than that of the control group (82. 3%). After treatment, the FEV1, FEV1%, FEV1/FVC were significantly higher than those before treatment, and the observation group was significantly higher than the control group (P<0. 01). During the treatment period, the inci-dence of adverse reactions such as palpitations, headache, tremor, and pharyngeal stimulation in the obser-vation group was not significantly different from that in the control group (P>0. 05). Conclusion The application of budesonide formoterol combined with Bailing capsule in the treatment of elderly patients with stable COPD is effective and safe, and it is worthy of clinical application.
作者
翟秀梅
袁晓梅
Zhai Xiumei;Yuan Xiaomei(First author's address Yongcheng People's Hospital,Yongcheng 476600,Henan,China)
出处
《临床心身疾病杂志》
CAS
2019年第5期144-146,共3页
Journal of Clinical Psychosomatic Diseases
关键词
慢性阻塞性肺疾病
稳定期
布地奈德福莫特罗吸入剂
百令胶囊
临床疗效
不良反应
Chronic obstructive pulmonary disease
stable period
budesonide formoterol inhaler
Bailing capsule
clinical efficacy
adverse reactions